BOSTON– Helus Pharma, formerly known as Cybin Inc., has rebranded and begun trading on the Nasdaq Global Market under the ticker symbol HELP, marking a key step in its transition toward becoming a commercial-stage pharmaceutical company focused on mental health treatments.
The company will operate under the business name Helus Pharma and will also continue trading on Cboe Canada under the same ticker symbol. The move includes a transfer of its U.S. stock exchange listing from the NYSE American, where it previously traded under the symbol CYBN. Helus Pharma said it plans to seek shareholder approval to formally change its legal name to Helus Pharma Inc. at its next annual and special meeting.
“Our new business name more accurately describes our compounds and reflects our anticipated transformation from a global clinical stage discovery and development company to a commercial-ready pharmaceutical company, with our two lead candidates HLP003 and HLP004,” said Eric So, interim chief executive officer. “Over the past several years, we have advanced our pipeline portfolio of differentiated, proprietary NSA drug candidates, which includes over 350 filed patents with more than 100 already granted.”
Helus Pharma is developing novel serotonergic agonists, or NSAs, designed to address major unmet needs in mental health care. Its most advanced program, HLP003, is in Phase 3 clinical development as an adjunctive treatment for major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. The company said preparations are underway for commercialization, subject to regulatory approvals.
A second lead candidate, HLP004, is being evaluated in a Phase 2 study for the treatment of generalized anxiety disorder, with topline data expected in the first quarter of 2026.
Company officials said the rebrand reflects an evolution from a discovery and development-focused organization to one preparing for commercialization, supported by patient-centered research and clinical development. The proprietary NSA compounds are designed to deliver durable mental health benefits through targeted mechanisms intended to support long-term recovery.
“This is an exciting new chapter for the Company,” So said. “With key data readouts for both HLP003 and HLP004 expected in 2026, we believe we are well positioned for commercialization with the potential to significantly enhance patient outcomes, introduce innovative therapies for healthcare providers, and deliver value to payers and shareholders.”
